Neurocrine Biosciences

Youtube Subscribe

Open: 110.89 Close: 110.97 Change: 0.08

You're losing the opportunity of using an AI to get informed about Neurocrine Biosciences.

Are looking for the most relevant information about Neurocrine Biosciences? Investor spend a lot of time searching for information to make investment decisions in Neurocrine Biosciences. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Neurocrine Biosciences are: Neurocrine, Biosciences, NA, stock, company, fearful, greedy, and the most common words in the summary are: neurocrine, stock, bioscience, market, best, news, price, . One of the sentences in the summary was: Jefferies Financial Group upped their price target on shares of Neurocrines …

Concept Map

Semantic Network

Stock Summary

Neurocrine Biosciences, Inc. discovers, develops, markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Its products include INGREZZA and DYSVAL, for the treatment of tardive dys.

Today's Summary

Neurocrine Biosciences stock has more room for growth in the near term. Jefferies Financial Group upped their price target on shares of Neurocrines to $123.00 in a research note on Monday, August 21st. Warren Buffett advises to be fearful when others are greedy.

Today's News

Neurocrine Biosciences Inc. per Employee $1.487M P/E Ratio 59.18 EPS $1.87 Yield N/A Dividend N-A Ex-Dividend Date 10/13/23. Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, has more room for growth in the near term. Warren Buffett advises to be fearful when others are greedy, and be greedy when people are fearful. Neurocrine Biosciences (NBIX) market cap & net worth - stock analysis. Use this Premium Home Analysis to view the latest news and analysis. Jefferies Financial Group upped their price target on shares of Neurocrine Biosciences to $123.00 in a research note on Monday, August 21st. Jefferies has a price target of $122.00 for shares. The company is set to give its latest quarterly earnings report on Tuesday.

Stock Profile

"Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California."

Keywords

This document will help you to evaluate Neurocrine Biosciences without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Neurocrine Biosciences are: Neurocrine, Biosciences, NA, stock, company, fearful, greedy, and the most common words in the summary are: neurocrine, stock, bioscience, market, best, news, price, . One of the sentences in the summary was: Jefferies Financial Group upped their price target on shares of Neurocrines to $123.00 in a research note on Monday, August 21st. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #neurocrine #stock #bioscience #market #best #news #price.

Read more →

Youtube Subscribe

---